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OBJECTIVE — We examined trends in incidence of treatment for diabetes-related end-stage
renal disease (ESRD) in the U.S.
RESEARCH DESIGN AND METHODS — Using the U.S. Renal Data System, we ob-
tainedthenumberofindividualshavingdiabeteslistedasprimarydiagnosiswhoinitiatedESRD
treatmentbetween1990and2006.IncidencewascalculatedusingtheestimatedU.S.population
withdiabetesfromtheNationalHealthInterviewSurveyandthenwasageadjustedbasedonthe
2000 U.S. standard population. Trends were analyzed using joinpoint regression.
RESULTS — The number of individuals who began diabetes-related ESRD treatment in-
creased from 17,727 in 1990 to 48,215 in 2006. From 1990 to 1996, the age-adjusted diabetes-
related ESRD incidence increased somewhat from 299.0 to 343.2 per 100,000 diabetic
population (P  0.45). However, from 1996 to 2006, the age-adjusted diabetes-related ESRD
incidence decreased by 3.9% per year (P  0.01) from 343.2 to 197.7 per 100,000 diabetic
population. Among individuals with diabetes aged 45 years, diabetes-related ESRD incidence
decreased by 4.3% per year (P  0.01) from 1990 to 2006. Among older individuals, incidence
increased during the 1990s but decreased in later years, by 3.9% per year (P  0.01) among
individuals aged 45–64, by 3.4% per year (P  0.01) among individuals aged 65–74 years, and
by 2.1% per year (P  0.02) among individuals aged 75 years.
CONCLUSIONS — Diabetes-related ESRD incidence in the diabetic population has de-
clined in all age-groups, probably because of a reduction in the prevalence of ESRD risk factors,
improved treatment and care, and other factors.
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E
nd-stage renal disease (ESRD) (i.e.,
kidney failure requiring dialysis or
transplantation) is a costly and dis-
abling condition with a high mortality
rate (1). In 2006, ESRD costs reached
nearly $23 billion, 6% of the Medicare
budget, and mortality rates were about
eight times greater among individuals
aged 20–64 years with ESRD treated by
dialysis than among those in the general
population of similar age (1). Diabetes is
the leading cause of ESRD in the U.S.,
accounting for 44% of new cases of
treatedESRDin2006(1).Inaddition,the
prevalence of diabetes continues to in-
crease (2) with nearly 24 million adults in
2007 with the disease (3). The incidence
of diabetes-related ESRD in the general
population, which is inﬂuenced by the
increasing number of individuals with di-
abetes, also continues to increase. How-
ever, diabetes-related ESRD incidence
among individuals with diabetes has de-
creased from 1997 to 2002 despite the
increase in the population living with di-
abetes (4). This analysis used data from
the U.S. Renal Data System (USRDS) to
examine recent trends in incidence of
treatment for ESRD in the population
with diabetes, which takes into account
the growing number of individuals with
diabetes, and to determine whether pre-
viously reported declining trends in this
population have continued.
RESEARCH DESIGN AND
METHODS— USRDS collects, ana-
lyzes, and distributes information from
clinical and claims data reports to the
Centers for Medicare and Medicaid Ser-
vices (CMS) regarding patients being
treated for ESRD, with oversight from the
National Institute of Diabetes and Diges-
tive and Kidney Diseases of the National
Institutes of Health. Through the ESRD
entitlement program, CMS reimburses
mostofthecostsofESRDtreatmentinthe
U.S. (5). USRDS includes demographic
and clinical data for almost all individuals
with ESRD in the U.S., including the date
patientswereﬁrsttreatedandtheprimary
diagnosis (5). Renal care providers are re-
quired to complete the CMS Medical Ev-
idence Report for each new patient with
ESRD regardless of Medicare eligibility
status. However, before 1995, the Medi-
calEvidenceReportwasrequiredonlyfor
Medicare-eligible patients (5).
The 1990–2006 USRDS data were
used to determine the overall number
of individuals in the U.S. with diabetes
listedastheprimarydiagnosiswhobegan
treatment (i.e., dialysis or kidney trans-
plantation) for ESRD. Thus, the term “in-
cidence” will be used to refer to initiation
of treatment for diabetes-related ESRD.
The primary diagnosis (i.e., primary
cause of renal failure) is taken from the
CMS Medical Evidence Report and is
based on the physician’s assessment of
the patient (5). Data were analyzed for
whites, blacks, and Hispanics. The racial
groups include individuals of both His-
panicandnon-Hispanicorigin;Hispanics
maybeofanyrace.Theannualnumberof
U.S. residents in whom diabetes is diag-
nosed was obtained from the weighted
sample of the civilian noninstitutional-
izedpopulationintheNationalHealthIn-
terview Survey (NHIS) using SUDAAN
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NHIS sample survey design. Incidence
rates were calculated using the number
of cases of diabetes-related ESRD and the
estimated population with diabetes and
then were age adjusted using the 2000
U.S. standard population. Standard er-
rors for incidence, assuming no variance
for the number of cases of diabetes-
related ESRD, were calculated using Tay-
lorserieslinearizationmethods(7)inSAS
(8). The NHIS estimate of the number of
U.S. residents with diabetes was unusu-
ally low in 1996, and the survey method-
ology was changed in 1997 (9). The low
estimate in 1996 and the survey redesign
in 1997 resulted in a large increase in the
number of individuals with diagnosed di-
abetes between 1996 and 1997. Hispanic
ethnicity data were not available in NHIS
before1997(9).Finally,joinpointregres-
sion analysis, which uses permutation
tests to identify the points (i.e., “join-
points”) where linear trends change sig-
niﬁcantly in direction or magnitude, was
used to assess trends over time (e.g., 0
joinpoints indicates a simple straight line
on the log scale) (10,11). The rate of
change for each trend was tested to deter-
minewhetheritwassigniﬁcantlydifferent
from 0 (e.g., no change), and each trend
in the ﬁnal model was described by an
annual percentage change (APC). Results
were considered signiﬁcant if P  0.05.
The ﬁgures plot the predicted diabetes-
related ESRD incidence values based on
the joinpoint regression models.
RESULTS— The total number of indi-
vidualswhobegantreatmentforESRDin-
creased from 49,868 in 1990 to 108,928
in 2006. Of these cases of ESRD, 17,727
(36%) were diabetes related in 1990 and
48,215 (44%) were diabetes related in
2006. Throughout this period, the num-
berofcasesofdiabetes-relatedESRDcon-
sistentlyincreasedforallage,sex-age,and
race-agegroups;italsoincreasedbetween
1997 and 2006 among Hispanics in all
age-groups.
From 1990 to 1996, the crude
diabetes-related ESRD incidence in-
creasedsigniﬁcantly,from285.4to421.9
per 100,000 diabetic population (Table
1). Age-adjusted incidence increased
nonsigniﬁcantly from 299.0 to 343.2 per
100,000 diabetic population. From 1996
to 2006, both crude and age-adjusted
diabetes-related ESRD incidence de-
creased, with the age-adjusted incidence
dropping from 343.2 to 197.7 per
100,000 diabetic population, a decline of
3.9% per year. Among individuals with
diabetes aged 45 years, diabetes-related
ESRD incidence decreased from 1990 to
2006, a 4.3% decrease per year (Table 1,
Fig. 1). From 1990 to 1996, among indi-
viduals aged 45–64 years, incidence in-
creased from 340.6 to 451.8 per 100,000
diabetic population and then declined
3.9% per year to 273.8 in 2006. Among
individuals aged 65–74 years, incidence
increased from 263.8 per 100,000 dia-
beticpopulationin1990to448.2in1998
Figure 1—Modeled age-speciﬁc incidence of diabetes-related ESRD in the population with dia-
betes,U.S.,1990–2006.Predictedvalues:Œ——Œ,45years;f——f,45–64years;F——F,
65–74years;——,75years.Predictedvaluesweremodeledusingjoinpointregressionanalysis.
Table1—Incidenceratesofdiabetes-relatedESRDandAPC,byage,sex,andraceorethnicity,
United States, 1990–2006
Incidence rate* Trend
1990 2006 Period APC (95% CI) P
Total 285.4 278.4 1990–1996 5.8 (3.5 to 8.0) 0.01
1996–2006 2.9 (3.6 to 2.2) 0.01
Total† 299.0 197.7 1990–1996 1.1 (1.9 to 4.1) 0.45
1996–2006 3.9 (4.7 to 3.1) 0.01
Age (years)
45 300.1 142.3 1990–2006 4.3 (5.1 to 3.4) 0.01
45–64 340.6 273.8 1990–1996 3.2 (0.6 to 5.9) 0.02
1996–2006 3.9 (4.6 to 3.2) 0.01
65–74 263.8 368.6 1990–1998 6.2 (3.2 to 9.2) 0.01
1998–2006 3.4 (5.4 to 1.4) 0.01
75 172.5 328.5 1990–1999 10.9 (8.9 to 12.9) 0.01
1999–2006 2.1 (3.7 to 0.3) 0.02
Sex†
Male 363.7 230.5 1990–2006 2.8 (3.6 to 1.9) 0.01
Female 250.6 168.6 1990–1996 2.4 (1.5 to 6.4) 0.20
1996–2006 4.3 (5.3 to 3.3) 0.01
Race†‡
White 266.2 164.7 1990–1996 1.3 (3.0 to 5.7) 0.53
1996–2006 5.0 (6.0 to 4.0) 0.01
Black 408.9 327.7 1990–2006 1.7 (2.9 to 0.6) 0.01
Ethnicity†§
Hispanic 306.7¶ 254.3 1997–2006 1.5 (3.3 to 0.3) 0.09
*Per 100,000 diabetic population. †Age-adjusted based on the 2000 U.S. standard population. ‡The racial
groupsincludepeopleofbothHispanicandnon-Hispanicorigin.§NHISbegancollectingHispanicethnicity
data in 1997. Hispanics may be of any race. ¶Data for 1997. APC, annual percent change.
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in 2006. Among individuals aged 75
years,incidenceincreasedfrom172.5per
100,000 diabetic population in 1990 to
380.0 in 1999 and declined from 1999 to
2006 by 2.1% per year to 328.5 per
100,000 diabetic population.
From 1990 to 2006, the age-adjusted
diabetes-related ESRD incidence was
higher among men than among women
(Fig. 2). Throughout this period, the age-
adjusteddiabetes-relatedESRDincidence
among men decreased at an average of
2.8% per year, from 363.7 per 100,000
diabetic population in 1990 to 230.5 in
2006 (Table 1). The decline in incidence
among women did not begin until 1996,
with the age-adjusted incidence decreas-
ing at an average of 4.3% per year, from
299.3 per 100,000 diabetic population in
1996 to 168.6 in 2006 (Table 1). Before
1996, the age-adjusted diabetes-related
ESRDincidenceamongwomendisplayed
a nonsigniﬁcant increase from 250.6 per
100,000 diabetic population in 1990 to
299.3 in 1996 (Table 1).
From 1990 to 2006, the age-adjusted
diabetes-related ESRD incidence by race
or ethnicity was highest among blacks
and lowest among whites (Fig. 2). During
this period, the age-adjusted diabetes-
related ESRD incidence among blacks de-
creased signiﬁcantly by 1.7% per year
from 408.9 per 100,000 diabetic popula-
tion to 327.7 (Table 1). However, among
whites, diabetes-related ESRD incidence
did not begin to decline until 1996, from
296.7 per 100,000 diabetic population to
164.7 in 2006, a decline of 5.0% per year
(Table 1). Among Hispanics, the age-
adjusteddiabetes-relatedESRDincidence
decreased between 1997 and 2006 but
not signiﬁcantly (Table 1).
CONCLUSIONS— We found that
diabetes-related ESRD incidence in the
population with diabetes has continued
to decline, which is consistent with a pre-
vious report (4) and suggests that current
efforts in prevention of ESRD may be suc-
cessful.Thedecreasingtrendsindiabetes-
related ESRD incidence are now being
seen in all age-groups, men, women,
whites, and blacks, unlike previously re-
ported data showing declining incidence
only among individuals aged 65 years,
women, and whites (4). However, from
1997 to 2006, diabetes-related ESRD
incidence among Hispanics did not de-
crease as it did among the other popula-
tions, so additional strategies are needed
to improve this trend.
Diabetes-related ESRD incidence de-
clined throughout the study period
among individuals with diabetes aged
45 years. Most individuals with diabe-
tes in this age-group are likely to have
type 1 diabetes, and intensive insulin
therapyhasbeenshowntoreducetherisk
of kidney disease in individuals with type
1 diabetes (12). Between 1999 and 2002
and 2003 and 2006, the proportion of in-
dividuals with diabetes aged 20–39 years
achieving glycemic control target levels
increased signiﬁcantly (13), suggesting
that improved glycemic control may have
contributedtothedecliningtrends.Inthe
older age-groups, diabetes-related ESRD
incidence began to decline in 1996 for
thoseaged45–64years,in1998forthose
aged 65–74 years, and in 1999 for those
aged 75 years. Reasons to explain the
decreasingtrendscannotbegleanedfrom
surveillance data but may include early
detection and management of kidney dis-
ease, improved treatment and care, better
control of ESRD risk factors (i.e., diabetes
and hypertension), or other factors (14–
16).Furthermore,newpharmacological
agents, such as ACE inhibitors and
angiotensin-receptor blockers, also
havebeendeterminedtoberenoprotec-
tive, independent of their ability to re-
duce blood pressure (17). Between 70
and 75% of patients aged 65 years
with diabetes and chronic kidney dis-
ease(CKD)useACEinhibitorsorangio-
tensin receptor blockers, and the
percentage is nearly 80% among those
aged 20–64 years (1).
An alternative explanation for the de-
cline in diabetes-related ESRD incidence
is that the large and sustained increase of
new cases of diabetes that has occurred
sincethe1990s(2)mayhaveledtoalarge
number of individuals who have not had
diabetes long enough to develop ESRD.
Furthermore, in 1997, the American Dia-
betes Association revised the diagnostic
criteria for diabetes, lowering the thresh-
old of the fasting glucose value from 140
to 126 mg/dl (18). This change may have
resulted in a greater number of individu-
alswithmilderdisease,detectedearlierin
the disease process. Once these patients
with new-onset, milder disease have had
diabetes long enough, it is possible that
the encouraging trends in diabetes-
related ESRD incidence may reverse. In
addition, it is possible that improved sur-
vival among individuals with diabetes
could lead to longer diabetes durations
and, thus, greater opportunity to develop
ESRD.
Even though diabetes-related ESRD
incidence in the population with diabe-
tes has decreased since 1996, diabetes-
related ESRD incidence in the general
population and the number of new
cases of diabetes-related ESRD continue
to increase, albeit at a slower rate (1,2).
Reducing the number of new cases of
diabetes-related ESRD will be difﬁcult
to achieve as our population ages and
Figure 2—Modeled age-adjusted incidence of diabetes-related ESRD in the population with
diabetes,bysexandraceorethnicity,U.S.,1990–2006.Predictedvalues:– – –,women;F——F,
men; Œ——Œ, whites; f——f, blacks; ——, Hispanics. Predicted values were modeled using
joinpoint regression analysis. The racial groups include individuals of both Hispanic and non-
Hispanic origin; Hispanics may be of any race. NHIS began collecting Hispanic ethnicity data in
1997.
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such as diabetes, continues to increase
(2). Nearly 24 million adults in the U.S.
had diabetes in 2007 (3), and 75% of
adults with diabetes have hypertension
(i.e., blood pressure 130/80 mm of
mercury or use prescription medica-
tions for hypertension) (16). Further-
more, 26 million U.S. adults were
estimated to have CKD (19), placing
thematriskofprogressingtoESRD.For
reasons that are not yet clear, individu-
alsbelongingtominoritypopulationsin
theU.S.mayprogressrapidlyfromCKD
to ESRD (20). Increased awareness of
the risk of developing kidney disease
among individuals with diabetes or hy-
pertension (21) and interventions, such
as blood glucose and blood pressure
control (22,23), to prevent or delay the
onset of kidney disease or reduce its
progression are needed to sustain and
improve trends in diabetes-related
ESRD incidence.
The ﬁndings in this report are sub-
ject to several limitations. First, data
were collected for individuals whose
ESRD treatment was reported to CMS;
those who died from ESRD before re-
ceiving treatment, those who refused
treatment, and those whose treatment
was not reported to CMS were not in-
cluded (5). Second, because the inci-
dence of diabetes-related ESRD was
deﬁned in terms of initiation of ESRD
treatment, changes in incidence may
have been due to changes in factors
other than disease incidence. These fac-
tors may include better access to ESRD
treatment or acceptance of treatment,
changesintreatmentandcarepractices,
greater recognition of the etiologic role
ofdiabetesinESRD,oracombinationof
these. The primary diagnosis was taken
from the CMS Medical Evidence Report
andwasbasedonthephysician’sassess-
ment of the patient (5), which may have
affected trends, especially if patients
had other ESRD risk factors such as hy-
pertension.From1999to2004,threeof
four individuals with diabetes also had
hypertension (16). Third, the estimated
populationwithdiabetesfromtheNHIS
was based on self-report and underesti-
matesthetotalpopulationwithdiabetes
in the U.S. Approximately 25% of indi-
viduals with diabetes have not had their
diabetes diagnosed (3). Fourth, the low
estimateofthepopulationwithdiabetes
in1996andthesurveyredesignin1997
resulted in a large increase in the num-
ber of individuals with diagnosed dia-
betes between 1996 and 1997 (9).
Despite the dip in the number of cases
between 1996 and 1997, joinpoint re-
gression analysis indicated that the
prevalenceandincidenceofdiabetesin-
creased steadily (i.e., without signiﬁ-
cant changes in direction or magnitude)
between 1990 and 2006 (2,24). Fur-
thermore, exclusion of the 1996 data
did not substantially affect diabetes-
related ESRD incidence trends (4).
More investigation is needed to deter-
mine what other factors might explain
the declining diabetes-related ESRD in-
cidence in the population with diabetes
since 1996. Finally, the correlation be-
tween the length of time diabetic pa-
tients had the disease and their risk for
developing diabetes-related ESRD was
not assessed because of a lack of data on
duration of diabetes.
Diabetes-related ESRD is a costly and
disabling condition with a high mortality
rate that continues to disproportionately
affect U.S. minority populations (1). In
2006, the age-adjusted diabetes-related
ESRD incidence among Hispanics and
blacks with diabetes was 1.5 and 2.0
times greater than that for whites. Inter-
vention programs to prevent ESRD and
eliminate racial/ethnic disparities should
aim to raise awareness about kidney dis-
easeandpromoteearlydiagnosis,prevent
and control ESRD risk factors, and im-
provepatientoutcomes,especiallyamong
populations with a greater burden of
ESRD. Continued surveillance of diabetes-
related ESRD using USRDS data will help
public health ofﬁcials monitor and assess
progress in lowering incidence and re-
ducing racial/ethnic disparities. New ini-
tiatives at the Centers for Disease Control
andPreventionarecurrentlyunderwayto
establish a national surveillance system
for CKD and its risk factors that can esti-
matethemagnitudeofdiseaseintheU.S.,
monitor trends, and identify groups at
risk (25).
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